Nurix Therapeutics Inc (NRIX)
22.05
-0.32
(-1.43%)
USD |
NASDAQ |
Nov 22, 16:00
21.50
-0.55
(-2.49%)
After-Hours: 20:00
Nurix Therapeutics Revenue (Quarterly): 12.59M for Aug. 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| August 31, 2024 | 12.59M |
| May 31, 2024 | 12.09M |
| February 29, 2024 | 16.58M |
| November 30, 2023 | 15.16M |
| August 31, 2023 | 18.47M |
| May 31, 2023 | 30.68M |
| February 28, 2023 | 12.68M |
| November 30, 2022 | 6.783M |
| August 31, 2022 | 10.79M |
| May 31, 2022 | 11.43M |
| February 28, 2022 | 9.621M |
| Date | Value |
|---|---|
| November 30, 2021 | 7.396M |
| August 31, 2021 | 10.25M |
| May 31, 2021 | 7.091M |
| February 28, 2021 | 5.011M |
| November 30, 2020 | 6.689M |
| August 31, 2020 | 4.085M |
| May 31, 2020 | 4.182M |
| February 29, 2020 | 2.864M |
| November 30, 2019 | 1.862M |
| August 31, 2019 | 10.58M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.862M
Minimum
Nov 2019
30.68M
Maximum
May 2023
10.32M
Average
9.936M
Median
Revenue (Quarterly) Benchmarks
| Enzo Biochem Inc | 7.526M |
| Neogen Corp | 216.96M |
| Pfizer Inc | 17.70B |
| Zymeworks Inc | 16.00M |
| Accolade Inc | 106.36M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -48.96M |
| Total Expenses (Quarterly) | 67.20M |
| EPS Diluted (Quarterly) | -0.67 |
| Enterprise Value | 1.114B |
| Profit Margin (Quarterly) | -388.9% |
| Earnings Yield | -13.20% |
| Normalized Earnings Yield | -13.20 |